Human isotope fractional absorption studies comparing chelated Magnesium Glycinate vs. Citrate vs. 4% Oxide, CYP2R1/CYP27B1 magnesium-dependent Vitamin D3 activation trials, and Metformin-induced Vitamin B12 holotranscobalamin depletion. Explore 4,327 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Variation in ICAM5 may influence abnormal dreams and cessation on varenicline.
First-line brigatinib treatment was associated with significant and clinically meaningful gains in Q-TWiST compared to crizotinib in patients with ALK-positive locally advanced or metastatic NSCLC,.
Triple FDC of DAPA + SITA + MET ER tablets once daily was significantly better in achieving blood sugar control versus dual combination once daily in patients with type 2 diabetes poorly controlled with metformin without any...
These findings confirm earlier reports of escitalopram efficacy in adolescents aged 12-17 years and extend the safety and tolerability data to children with GAD aged 7-11 years.
LY IGlar and IGlar had equivalent efficacy in glycaemic control and similar safety profiles in Chinese patients with T1DM, when used in combination with mealtime insulin lispro.
Non-inferiority of 2 PLD dosing schedule was not confirmed because the trial was closed prematurely.
Combinations of empagliflozin/linagliptin as second-line therapy for 52 weeks significantly reduced HbA1c compared with the individual components and were well tolerated.
Addition of dapagliflozin to metformin provides a new therapeutic option for treatment of type 2 diabetes in patients who have inadequate glycaemic control with metformin alone.
Atez/Bev-related kidney/urinary, skin/subcutaneous, and mild vascular AEs were associated with favorable survival outcomes in HCC, whereas metabolism/nutrition, hepatobiliary, and severe gastrointestinal AEs were associated...
Three additional years of adjuvant imatinib reduces the risk of relapse in patients who have received 3 years of adjuvant imatinib with an acceptable tolerance.
In Chinese patients with PsA, tofacitinib efficacy was greater than placebo (primary and secondary endpoints).
The blood lipid levels of both control and evolocumab groups stabilized after 1 month.
Adjuvant chemotherapy after curative resection in patients with locally advanced ESCC reduced early recurrence but had no statistically significant increase in the long-term disease-free survival.
The incidence of side effects was similar between the groups.
Patients undergoing vascular surgery show deterioration in their kidney function during the first year, despite statin therapy.
Our findings indicate that statin therapy intensified by ezetimibe may reduce the incidence of heart and blood vessel events within the first 12 months after vascular surgery.
Treatment-related side effects were comparable in the two groups.
Galcanezumab was associated with statistically significant changes from baseline in the PRO measures across the entire 12-month treatment period.
201 participants (mean [SD] age, 49 [11] years; mean [SD] body weight, 91.9 [18.2] kg; 87 [43.3%] female; 51 [25.4%] with T2D) were randomized to semaglutide (n = 134) or placebo.
In children with moderate-to-severe asthma and type 2 inflammation, treatment with dupilumab plus medium-dose ICS reduced exacerbations and improved lung function and asthma control compared with placebo plus continued...
INCS did not affect the nasal inflammatory biomarker profile in children with OSAS, including the responders.
Conclusions: The high placebo response in this study prevented the detection of an effect of levomilnacipran in children and adolescents.
Enavogliflozin, added to metformin plus gemigliptin, was well tolerated and as effective as dapagliflozin in the treatment of patients with T2DM.
This study failed to demonstrate the benefit of concomitant and maintenance TMZ in newly diagnosed PCNSL.
Clinically relevant improvements in HJHS were observed in younger PwHA and those with target joints after 48 weeks of emicizumab in HAVEN 3.
A total of 134 patients were enrolled.
In hypertensive patients with ECG left ventricular hypertrophy with existing or new irregular heartbeat (AFib), digoxin use is not associated with a significantly increased risk of all-cause mortality after adjusting for other...
Nivolumab plus gemcitabine-cisplatin showed a trend towards improved OS and PFS outcomes in the Asian population, suggesting that the combination therapy may serve as a new treatment option for patients from Asian countries...
Pioglitazone added to metformin and alogliptin significantly improved blood sugar control in patients with type 2 diabetes, and was non-inferior to dapagliflozin.
Results confirm the robustness of DTG/3TC as a switch option in virologically suppressed females with HIV-1, with outcomes similar to those in males.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
